Psychedelic Research in
Croatia
Croatia has a small but identifiable psychedelic-adjacent research footprint, led here by one active linked trial on esketamine in depressive disorder. The evidence base in the country appears concentrated in depression-related neuropsychiatry rather than broad psychedelic medicine.
Key Insights
A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Croatia.
- 1
The country's current activity is depression-focused rather than centred on classic psychedelics, matching the single linked active esketamine trial.
- 2
Croatia's legal framework appears restrictive for controlled psychedelic compounds, with access mainly limited to standard pharmaceutical channels and research settings.
- 3
EU authorisation of Spravato creates a clearer pathway for esketamine than for psilocybin, MDMA or related substances.
- 4
The available sources do not indicate a broad domestic clinical psychedelic programme or a large institutional network; the ecosystem looks small and early-stage.
- 5
Because access practice can vary by hospital, prescriber and import/supply arrangements, claims about real-world availability beyond authorised medicines should be treated cautiously.
Research Snapshot
Blossom currently tracks 1 psychedelic clinical trial connected to Croatia, including 1 active study.
- Active trials
- 1
- Total trials
- 1
- Stakeholders
- 0
- Events
- 1
Currently active in Blossom
Country-linked records
No linked stakeholders
Linked event records
Top Compounds
- Esketamine(1)
Top Study Topics
- Treatment-Resistant Depression (TRD)(1)
Active Trial Preview
View all trials →Medical Access Snapshot
Croatia classifies most classic psychedelic compounds as controlled substances under its Law on Combating Drug Abuse; possession of small amounts was decriminalized as a misdemeanour in 2013 but medical/therapeutic access is limited. The only psychedelic-derived medicine with an EU marketing authorisation (esketamine/Spravato) is authorised at the EU level and may be supplied in Croatia under usual pharmaceutical channels, while ketamine is available as an approved anaesthetic and is used off-label in some private settings for psychiatric indications...
Regulatory Status
Croatia's Law on Combating Drug Abuse places narcotic drugs and psychotropic substances under national control, so compounds such as psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine and mescaline do not have routine authorised therapeutic access unless covered by a specific research or medicines pathway. Esketamine (Spravato) has EU-wide marketing authorisation for treatment-resistant depression and is administered under prescription and clinical supervision, which supports a narrow legal access pathway in Croatia. Ketamine is listed in Croatian narcotics/psychotropics rules and is used as a medicine in standard medical practice, but psychiatric off-label use would depend on local clinical governance rather than a dedicated psychedelic policy framework. ([narodne-novine.nn.hr](https://narodne-novine.nn.hr/clanci/sluzbeni/2001_12_107_1756.html?utm_source=openai))
Country Details
- Region
- Europe
- Last updated
- 4 May 2026
Country Report
Medical Only (Private)Medical Access and Reimbursement
Croatia classifies most classic psychedelic compounds as controlled substances under its Law on Combating Drug Abuse; possession of small amounts was decriminalized as a misdemeanour in 2013 but medical/therapeutic access is limited. The only psychedelic-derived medicine with an EU marketing...
Open access guide →Research Events in Croatia
Conferences, trainings, and research gatherings connected to the country report.
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Croatia.